M
Marc A. Pohl
Researcher at Cleveland Clinic
Publications - 31
Citations - 8123
Marc A. Pohl is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Renal function & Creatinine. The author has an hindex of 17, co-authored 30 publications receiving 7738 citations.
Papers
More filters
Journal ArticleDOI
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
Edmond J Lewis,Lawrence G. Hunsicker,William R. Clarke,Tomas Berl,Marc A. Pohl,Julia B. Lewis,Eberhard Ritz,Robert C. Atkins,Richard D. Rohde,Itamar Raz +9 more
TL;DR: The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
Journal ArticleDOI
The natural history of atherosclerotic and fibrous renal artery disease.
TL;DR: Individuals identified with progressive azotemia due to renal artery stenosis may benefit from improved perfusion flow by renal revascularization or balloon angioplasty provided no significant parenchymal disease is present.
Journal ArticleDOI
Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations
Marc A. Pohl,Samuel S. Blumenthal,D. Cordonnier,Fernando De Alvaro,Giacomo Deferrari,Gilbert M. Eisner,Enric Esmatjes,Richard E. Gilbert,Lawrence G. Hunsicker,José B. Lopes de Faria,Ruggero Mangili,Jack Moore,Efrain Reisin,Eberhard Ritz,Guntram Schernthaner,Samuel Spitalewitz,Hilary Tindall,Roger A. Rodby,Edmund J. Lewis +18 more
TL;DR: A SBP target between 120 and 130 mmHg is recommended, in conjunction with blockade of the renin-angiotensin system, in patients with type 2 diabetic nephropathy, and Progressive lowering of SBP to 120mmHg was associated with improved renal and patient survival, an effect independent of baseline renal function.
Journal ArticleDOI
Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.
Daniel C. Cattran,Gerald B. Appel,Lee A. Hebert,Lawrence G. Hunsicker,Marc A. Pohl,Wendy E. Hoy,Douglas R. Maxwell,Cheryl L. Kunis +7 more
TL;DR: This study suggests that cyclosporine is an effective therapeutic agent in the treatment of steroid-resistant cases of MGN, and 39% of the treated patients remained in remission and were subnephrotic for at least one-year post-treatment, with no adverse effect on filtration function.
Journal ArticleDOI
A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis
Daniel C. Cattran,Gerald B. Appel,Lee A. Hebert,Lawrence G. Hunsicker,Marc A. Pohl,Wendy E. Hoy,Doug R. Maxwell,Cheryl L. Kunis +7 more
TL;DR: In this article, a clinical trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis (FSGS) was conducted and the short and long-term effects on renal function were assessed.